Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phambili: MRKAd5 HIV-1 Vaccine in South Africa
NCT00413725Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2007
- Primary completion
- Aug 2012
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MRKAd5 HIV-1 gag/pol/nef vaccine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2007; status: completed.
02
Drugs
MRKAd5 HIV-1 gag/pol/nef vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00413725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413725.